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Abstract:   
Complement immunobiology, and with it complement analysis, has undergone a 
renaissance in the past decade.  Classically, complement analysis involved a limited 
number of tests on C3, C4 and CH50 and was performed in highly esoteric laboratories.  
This is rapidly changing with routine laboratories now being called upon to do a rapidly 
expanding menu of testing and to do that testing more expeditiously.  This is the result 
of the growing recognition of the role played by complement dysfunction in many more 
diseases and disorders and the concomitant increase in interest in complement 
targeting therapeutics.  In response, laboratories specializing in complement analysis 
have joined with the International Complement Society to coordinate efforts to 
standardize and improve complement testing, ongoing efforts that have already borne 
fruit.  A recognition of the power of complement analysis has brought forward new 
testing and a new realization of the importance of post-draw specimen handling, as well 
as awareness of the potential for confounding changes in an individual subject. The 
increased usefulness of complement testing and the work to standardize and expand it 
means the future is strong for complement analysis.   
 
Changing Landscape of Complement Testing: Growing Clinical Importance 
For decades the primary, and nearly exclusive, use of complement testing was to 
test for primary immunodeficiencies or to test for disease activity in systemic 
autoimmune diseases, with a limited number of rheumatological or nephrology disorders 
(Ricklin, Hajishengallis et al. 2010, Skattum, van Deuren et al. 2011, de Cordoba, 
Tortajada et al. 2012, Holers 2014). Only a small number of tests were used, mainly to 
assess total complement function, C3 and C4.  While specificity was important, not a 
great deal of sensitivity was needed.  With the abundance of components of 
complement in circulation, C3 being the highest at 1 to 1.5 mg/mL, the presence or 
absence of the proteins in the cascade could be measured by relatively simple methods 
(Morley and Walport 2000).  However, the field has changed dramatically due to 
significant developments in complement science.  First, there has been a notable 
increase in the number of diseases and disorders recognized to have complement 
involvement (Table 1) (Thurman and Holers 2006, Hajishengallis, Reis et al. 2017).  The 
diseases now recognized to connect to complement are anatomically diverse, ranging 
from the kidney to the eye, as well as ranging from the rare atypical hemolytic uremic 
syndrome to common disorders like age-related macular degeneration.  The 
pathophysiology of these disorders often traces back to the strong pro-inflammatory 
properties of complement which can affect so many properties of biology in so many 
tissues and organ systems. That can, in turn, be traced back to the original task of 
complement which is to fight infection.  As a first line of defense, complement has a 
powerful potential to tag and even destroy invading microbes while activating the larger 
immune system to clear the potential damage (Walport 2001, Skattum, van Deuren et 
al. 2011). These are functions that can be very damaging if turned on the host tissues.  
Many of the complement-connected disorders are, unsurprisingly, associated with an 
inappropriate over-activation of complement or with a failure to control complement.  
Some of these activations or losses of control, such as seen for mutations in 
complement Factor H, can be far more subtle than the yes or no deficiency historically 
diagnosed by a clinical lab (Jozsi, Tortajada et al. 2015, Medjeral-Thomas and Pickering 
2016, Parente, Clark et al. 2017).  The mutations can involve subtle changes in 
function, changes limited to circulation or to those on a surface.  Detecting these more 
nuanced changes in complement requires more nuanced testing in the diagnostic 
laboratory.  
The second event that has changed the landscape for complement testing was 
the advent of therapeutics that directly target complement (Ricklin, Mastellos et al. 
2017).  Starting in 2007, the first complement-specific therapeutics entered the market. 
With this there is a need to not only diagnose the disease but also follow the treatment.  
This changed the analysis from needing to show only if a complement component were 
deficient to needing to know if the function was suppressed to 10% of normal, for 
example (Prohaszka, Nilsson et al. 2016).  This led to the development of new assays 
and to the appreciation of new values in existing, but formerly rare or esoteric, tests.  In 
addition, it has helped propel efforts to improve the standardization between 
laboratories and the quality of complement testing overall.  This means existing 
laboratories specializing in complement have improved, plus there is now an increase in 
complement testing in the more general, large laboratories.  This produces more 
pressure for the tests to be robust and approachable (Mollnes, Jokiranta et al. 2007).  
The system that needs this robust testing is a set of proteins involved in the 
interconnect cascade of pro-enzymes, enzyme regulatory proteins, recognition 
molecules, signing molecules and the receptors that constitute complement.  
Complement was first described in the late 1800’s, but the list of components continues 
to grow. The complement system is composed of more than 30 proteins. This cascade 
as long been known for its ability to kill invading microbes at first exposure.  As part of 
the innate immune system, differentiation of self from non-self involves important 
tagging of self and control of complement on host surfaces (Zipfel and Skerka 2009, 
Ricklin, Hajishengallis et al. 2010). 
 
Importance of complement functional testing:   
Some of the earliest testing performed for complement was functional testing, 
and the utility and interest in the analysis of function of complement remains 
(Prohaszka, Nilsson et al. 2016).  In one functional assay it is possible to test for the 
presence and functionality of all the components of an activation pathway and the 
terminal pathway at once (Figure 1A).  This ability to broadly test for complement 
function of a number of components of the cascade has led to the testing being referred 
to as a “Total Complement Activity” test, but it generally references the classical 
pathway functional assays.  Functional complement testing proved very useful in 
screening for an immunodeficiency or complement activation with consumption.  For 
immunodeficiency testing the more common classical pathway activity test (also called 
'CH50') is combined with an alternative pathway activity (or AH50) assay to quickly 
determine where in the pathway a deficiency lies; classical, alternative, or the shared 
terminal (Figure 1A).  This dramatically reduces the work required to determine the 
specific component deficiency.  On the activation side, if a patient has an ongoing 
complement consumption that in turn depletes the amount of available complement that 
reduction is reflected in a decreased measurable function.  This has proved useful for 
testing for flares in autoimmune disease (Spronk, Limburg et al. 1995, Leffler, 
Bengtsson et al. 2014).  This utility has been the prime driver in the development of the 
now multiple methods for testing complement function.  The types of complement 
functional analysis largely fall into three categories, each with their own benefits and 
disadvantages.  What these tests share is a need to first activate the specific pathway of 
interest, then measure the formation of the terminal complement complex in solution or 
by functional outcome.  The buffer components, or the addition of inhibitory antibodies, 
are used to keep the other activation pathways in check. For example, the inclusion of 
calcium chelators (e.g. EDTA) can inhibit the classical pathway through destablization of 
the C1 complex (Eagle and Brewer 1929, Kabat and Mayer 1961).  The most historic 
form of complement function testing is what is referred to as a hemolytic test.  In this 
method, an animal red blood cell (RBC), generally a sheep RBC, is coated with 
antibodies (hemolysin) making it an optimal target for classical pathway recognition.  
This recognition leads to activation which then results in the formation of the membrane 
attack complex (MAC) on the surface of the red blood cell.  The MAC leads to lysis of 
the RBC and release into solution of the hemoglobin (Kabat and Mayer 1961).  The 
hemoglobin is easily quantitated by spectrophotometry which can then be related back 
to the percentage of RBC’s that were lysed and the functionality of complement to do 
the lysing.  As this is a sequential cascade involving the whole pathway, the relation 
between the concentration of serum and the amount of lysis is not linear.  It is instead 
more sigmoidal, following the von Krug equations (Jackson, Basinger et al. 1970).  
Therefore, the traditional method for running a hemolytic assay was to run a five-point 
serial dilution of serum or plasma, then use the three points that form the most linear 
portion of the curve that covers the mid-point of lysis, where half the RBC are lysed. 
From there the dilution that would lead to lysis of exactly 50% of the RBC is calculated, 
and the result reported as the reciprocal of that dilution (Kabat and Mayer 1961).  Some 
of the newer methods instead will report results as percentage of a normal or standard 
value.  For the hemolytic method it is the relation to the report of the 50% lysis point that 
gives the test the abbreviated CH50 for the classical pathway assay.  A similar assay, 
the AH50, can be performed where the target RBC is of rabbit or chicken origin, not 
from sheep, which is an activating surface for the alternative pathway; the classical 
pathway is kept inactive by chelating  calcium (e.g. by EGTA) necessary to maintain the 
C1 complex.  These hemolytic assays have the advantage of having the greatest 
sensitivity at the low end of function. Since they are also so complex, however, a 
specialized laboratory is required.  Because they rely on live cells, there is the potential 
for variability in supply that needs to be very carefully controlled.   
 The most common method used in US clinical laboratories for measuring total 
complement is based on lysis of a liposome.  In this assay a synthetic liposome stands 
in for the RBC of the hemolytic assay.  The liposome is loaded with an enzyme, such as 
glucose-6-phosphate, that is easily measured on a common clinical laboratory 
chemistry analyzer (Frazer-Abel, Sepiashvili et al. 2016).  As for the CH50, the liposome 
is coated with antibody to activate the classical pathway, one concentration of serum or 
plasma is then used in the reaction mixture and the amount of enzyme release is 
measured.  This assay is very well suited to a large hospital-type laboratory, as it is 
automated with high throughput, thus fairly inexpensive to run.  This testing has proven 
very useful when a fast yes or no answer is needed, but there is evidence that this type 
of assay is not sufficiently sensitive for monitoring nuanced changes at either end of the 
functional spectrum (Gatault, Brachet et al. 2015).  It is important to keep this in mind 
when measuring low levels of remaining function in order to monitor the effectiveness of 
a therapeutic complement blockade.  
 A more recent addition is the ELISA style complement function assays.  There 
are currently at least three commercially available forms of the classical pathway 
function assay that have regulatory approval in the US (Quidel & DiaSorin) or in the EU 
(Wieslab, Eurodiagnostica).  These assays have rapidly gained popularity and are now 
utilized by an increasing number of laboratories.  As an ELISA style assay, it is well 
suited to being run in an immunology laboratory without access to high quality RBC and  
without requiring the same level of expertise in complement analysis.  While the three 
assays differ they all utilize antibodies on the plate, or complexes in solution, to activate 
the C1 complex and then measure the production of the membrane attack complex, a 
measure of the level of complement activation that occurred. Wieslab also has kits for 
the alternative and lectin pathway function which afford a more complete investigation of 
complement function (Mollnes, Jokiranta et al. 2007).  Like the liposomal assay, these 
are largely regulatory-approved assays for patient diagnostics, and therefore they have 
the benefit of strong supply chain control, low lot-to-lot variability and higher throughput 
than the traditional hemolytic assay.  Depending on the assay and the way the data is 
calculated, the sensitivity can be better than the liposomal assay at the lower end of 
function.  This makes these assays generally well suited to follow the therapeutic 
blockade of complement, perhaps trading some low level detection for more consistent 
quantitation and reproducibility than the hemolytic assay generally.   
 For the monitoring of complement blockade by therapeutics, the functional 
assays remain the most common assay.  However, there is growing interest in 
measuring the split products (C4d, C3a, C3d or Bb) and complexes (sC5b-9) to look at 
the level of complement activation or inhibition.  These assays have the potential to add 
more detail and sensitivity to the functional assays.  Measurements of the soluble 
terminal pathway activation complex sC5b-9 (sometimes referred to as soluble 
membrane attack complex, sMAC) can assess potential response level to complement 
blockade as well as monitor the completeness of that blockade.  There have been some 
documented issues related to the consistency of results between laboratories (Bu, 
Meyer et al. 2015), however, measurements of the inhibition of the convertases has 
been found by some laboratories to be a promising method for stratifying patients.  This 
testing is currently available in a limited number of laboratories (Blom, Volokhina et al. 
2014).   
 The value of measuring activation products can be twofold.  First, they pinpoint 
one pathway or component.  This has the potential to test the level of control of an 
individual component, in addition to being able to differentially specify which pathway is 
activated or inhibited (Frazer-Abel, Sepiashvili et al. 2016).  As well as differentiating the 
point of activation or control, measurement of the split products or complexes can be 
more sensitive than the measurement of total function (Frazer-Abel, unpublished data).  
The functional assays interrogate the whole pathway, so it is not possible to determine 
the specific rate-limiting component nor the step in the pathway.  Combining 
complement activation markers can reveal the point of inhibition and if that inhibition 
affects the upstream portion of the cascade or if the underlying complement activation is 
still in process (Figure 1B).   
 
Complication of specimen handling:   
 Historically one of the bigger impediments to the adoption of complement testing 
by physicians has been the potential issues around ex vivo activation of complement 
and the resulting uncertainty of the results.  It has long been known that if serum and 
plasma for complement analysis are not handled correctly, the results can differ greatly 
from the values for the patient at the time of draw.  Work from Mollnes and colleagues 
demonstrated some pretty remarkable increases in the levels of activation fragments 
after storage a 4C (Mollnes, Garred et al. 1988).  In work by Yang et al., they 
concluded that if EDTA was included in the sample at a concentration of > 10mM the 
levels of C3a, C4d, C5a and sC5b-9 were consistent for four hours at room temperature 
and 24 hours at 4oC (Yang, McGookey et al. 2015).  An important note for this testing 
was that it was performed on collections from normal individuals.   A lot of testing for 
diagnostics or clinical trials will be performed on specimens from individuals with 
ongoing complement activation, due to the presence of complement activators (immune 
complexes, cryoglobuline, paraproteins, septic samples, etc.), or dysregulation in the 
sample.  If there is strong baseline in vivo activation there is the possibility of more ex 
vivo activation.  For one patient, the level of C4a measured increased after one hour at 
room temperature and doubled at four hours. This variable has been found among 
patients, with some results remaining consistent over time. (unpublished data, Frazer-
Abel). If you look at the specimen production instructions for a complement specialty 
laboratory or the instructions for sample preparation included in a complement kit 
inserts, the recommendations will be to get the specimen processed and frozen at -
80oC within an hour, or at most two hours.  Even then there is data that storage at -80oC 
is not sufficient to stabilize complement for extended storage, over six to 10 years 
(Morgan, O'Hagan et al. 2017).   
 In addition to sample handling concerns, there are also considerations around 
the subject.  One of these factors can be the level of stress in the subject.  Work from 
Burns et al. 2008 demonstrated marked increases in complement activation fragments 
in response to a psychological stress (Burns, Edwards et al. 2008).  Normal subjects 
were giving a paced auditor serial addition task (PASAT) which has been shown to 
cause stress responses in individuals. For this testing an additional burst of noise was 
included for each incorrect answer. C3a and Bb levels increased markedly at the time 
the task was performed while C5a increased 30 minutes after the test.  Of potential 
importance for this study, all testing was performed in the afternoon. This is important 
because there is some data on the effect of the circadian rhythm and sleep on 
complement levels.  Work from Reis et al. in 2011 looked at the levels of C3 and C4 as 
well as the split product C3a over the circadian cycle (Reis, Lange et al. 2011).  C3 and 
C4 levels decreased during the night, but the change was independent of the sleep-
wake cycle.  C3a, by contrast, increased at night but that increase was lost if the subject 
did not sleep.  While there was some controversy around the circadian cycle effect on 
complement, there is clearly enough data to consider it a possibility.  These factors 
point to the value of obtaining baselines levels on a patient or subject, if possible. While 
there are reference ranges for the complement components, there are also individual 
differences.   
 
Progress and efforts to standardize complement analysis:   
 With this increased attention and the new demands on complement testing, it 
was clear to the experts that there was a need to improve the consistency and quality of 
the testing.  From this recognized need, a standardization and quality committee was 
developed out of the XXIInd International Complement Workshop.  In 2009, Dr. George 
Füst, of Semmelweis University, Third Department of Internal Medicine, Budapest 
(Hungary) was elected the chairman. The Sub-Committee for the Standardization and 
Quality Assessment of Complement Measurements was formally recognized and 
became part of the IUIS Quality Assessment and Standardization Committee 
(Prohaszka, Nilsson et al. 2016).  Since that time seven rounds of external quality 
assessment, now covering 18 parameters (function, proteins, activation products and 
autoantibodies), have been completed.  These efforts have shown the need for such 
standards and resulted in improvements in the consistency of testing across 
participating institutions, while extending the global reach of the efforts.   
 Now that these efforts are well underway and bearing fruit, efforts have turned to 
creating a recognized standard with defined amounts of the individual components.  
These efforts are necessary because currently there is only one WHO standard that 
includes a limited number of complement analyses; it is now over 40 years old and 
increasingly difficult to obtain (1st International Reference Preparation, 1980, Code 
W1032; Document 80.1281; Human serum complement components C1q, C4, C5, 
factor B, and whole functional complement CH50).   
 
Future of complement analysis? 
 Now that complement testing has moved beyond C3, C4 and CH50, it is unlikely 
to ever revert to the quiet recesses of esoteric testing.  Complement is recognized to 
have roles in both devastating rare diseases and more common inflammatory and 
immunological disorders, so complement testing will only increase and improve.  And 
while there have been substantial changes already, it is unlikely that the pace of these 
changes will slow.  For example, multiplex analysis of complement has recently become 
available commercially in the Luminex format (Millipore Corp), and a number of other 
modalities are also being pursued in individual laboratories (e.g., Mass Sped and MSD 
Mesoscale).  Having more quality testing available can only aid in connecting 
complement to other places where it is a factor.  Combining that with the potential for 
low volume requirements, the possibility of multiple results and the increased sensitivity 
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Inflammatory disease Vasculitis, Nephritis,  Glomerulonephritis (GN), Systemic inflammatory reaction syndrome 
(SIRS), sepsis, ischemia/reperfusion injury (I/R 
injury), Crohn’s disease, haemolytic uremic 
syndrome (HUS), atypical haemolytic uremic 
syndrome (aHUS), Rheumatoid arthritis (RA), 
Hereditary angioedema (HAE) 
Autoimmune disease SLE, Multiple sclerosis, Acute myasthemia 
gravis (AMI), Psoriasis, Paroxysmal nocturnal 
hemoglobinuria (PNH) 
Neuro-degeneration disease Alzheimer’s disease, age-related macular 
degeneration (AMD) 
Others Transplant rejection, Stroke, Myocardia 
Infarction, trauma, burn, capillary leak syndrome, 
biomaterials incompatibility (dialysis, 
cardiopulmonary bypass, plasmapheresis, etc.) 
Figure 1A:  The Functional Complement Assays.  The components involved in each of 
the complement functional assays is depicted.  The classical pathway function is 
shown with orange arrow, the lectin pathway functional assay in green and the 
alternative pathway in blue.  For each of these tests the presence and functionality of 
each component for that activation pathway and the terminal pathway is required.  
 
Figure 1B: The Complement Activation Markers.  The activation or inhibition of the 
complement system can be monitored by measuring the levels of activation fragments 
or assessing the convertase.  These individual markers also have the benefit of being 
able to distinguish activation or inhibition of the individual pathway.  Circles indicated 
activation markers.  Colors correspond to the pathway involved.  Two colors indicated 
two pathways can produce that fragment.    
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